Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAnna CandoniPDPierre‐Yves DumasMRMenno Van Roosmalen

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows real-world data on overall survival in AML with Ivosidenib plus Azacitidine, suggesting ongoing need for evidence.

Key Points

  • This study aims to describe overall survival outcomes in AML patients treated with Ivosidenib and Azacitidine using real-world data.
  • Utilized the TriNetX Dataworks Platform for a retrospective cohort study.
  • Identified adult patients with newly diagnosed AML treated with Ivosidenib plus Azacitidine.
  • Collected data from electronic medical records, including demographics and treatment duration.
  • 23 patients received Ivosidenib plus Azacitidine, with a median follow-up of 21.2 months.
  • One-year overall survival rate was approximately 79.6% from diagnosis in this cohort.
  • Overall survival outcomes were consistent with those observed in clinical trials, despite limited patient numbers.

Cite This Study

Candoni et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da59https://doi.org/10.1182/blood-2025-3401
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo2025 · 1 citations
  2. 2Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study2025
  3. 3A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in <i>IDH1</i> -mutated acute myeloid leukemia (AML).2026
  4. 4Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)2025 · 3 citations
  5. 5A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress2025